?? Why This Matters
ARPA-H represents the most significant shift in U.S. biomedical funding strategy in 50+ years. Unlike NIH's traditional peer-review model that favors incremental science, ARPA-H embraces a DARPA-style "program manager as entrepreneur" model where visionary leaders with $50-200M budgets pursue transformative breakthroughs deemed "too risky" for conventional funding.
With a $2.5 billion annual budget by 2024 and congressional mandate to operate outside traditional NIH constraints, ARPA-H is catalyzing innovations in organ-on-chip platforms, AI-driven drug discovery, precision diagnostics, and cellular reprogramming that could compress decades of incremental progress into years of radical advancement. For Patient Analog stakeholders, ARPA-H funding represents unprecedented opportunity to accelerate human simulation technologies from research tools to clinical standards.
?? AGENCY OVERVIEW
ARPA-H (Advanced Research Projects Agency for Health) was established in 2022 through bipartisan legislation[1] with an initial $1 billion budget, expanded to $2.5B by 2024. Modeled after DARPA's high-risk, high-reward approach that created GPS, the internet, and mRNA vaccine platforms, the agency funds transformative projects in cancer, Alzheimer's, diabetes, and emerging infectious diseases that traditional funding mechanisms cannot support.
The agency operates with unprecedented flexibility: program managers can commit multi-year funding without annual appropriations battles, bypass traditional peer review, and pursue "DARPA-hard" challenges where success probability may be 10-30% but potential impact is civilization-changing.
?? ARPA-H ESTABLISHMENT TIMELINE
??? ORGANIZATIONAL STRUCTURE
Director's Office
Dr. Renee Wegrzyn, Director: Reports directly to HHS Secretary (bypassing NIH hierarchy). Authority: approve programs up to $200M, hire program managers with 4-year terms, waive standard procurement rules. Background: DARPA biological technologies, synthetic biology commercialization. Management style: Hands-off with program managers, aggressive on transition to practice.
Program Managers (PMs)
Core of ARPA-H's innovation model. Each PM controls $50-200M budget with 4-year term (no renewal—forces urgency). Recruitment profile: PhD scientists with entrepreneurial/operational experience, not traditional academics. Compensation: Government GS-15 pay (~$150K) plus prestige of launching billion-dollar programs. Current PMs span synthetic biology, bioelectronics, computational medicine, advanced diagnostics.
Innovation Hubs
Boston Hub (Investor Ecosystem): Focus on technology commercialization, startup engagement, venture integration. Programs: DASH diagnostic accelerator, precision surgery platforms.
Chicago Hub (Health Equity): Community health interventions, wearable diagnostics, pandemic preparedness. Programs: RESILIENT proactive health, PARADIGM countermeasure platforms.
Atlanta Hub (Health Tech): Medical device innovation, AI clinical decision support, advanced therapeutics. Programs: PROTEUS programmable biologics, cellular manufacturing.
Transition Office
Critical differentiator from NIH basic research. Dedicated team ensures ARPA-H innovations reach clinical use: FDA regulatory pathways, reimbursement strategies, commercial partnerships, health system adoption. Metrics: Number of technologies entering clinical trials, FDA submissions, product launches—not just publications.
?? FLAGSHIP PROGRAMS IN DETAIL
PROTEUS - Programmable Therapeutics
Mission: Create next-generation biologics that can be programmed and reprogrammed to adapt to patient-specific disease states, eliminating "one-size-fits-all" limitations of current therapeutics.
Total Investment: $150M over 4 years across 12 performer teams
Key Technologies: (1) Self-regulating CAR-T cells with biosensor feedback loops, (2) mRNA therapeutics with conditional expression circuits, (3) Synthetic biology platforms for rapid therapeutic prototyping, (4) Organ-on-chip systems for personalized therapy testing.
Performer Highlights: MIT (programmable T-cell receptors), UCSF (organ chip CAR-T optimization), Ginkgo Bioworks (biological circuit design automation), Emulate (liver-kidney chip for dosing personalization).
Milestones: Year 1×proof-of-concept in humanized mice; Year 2×organ chip validation of programmable circuits; Year 3×IND-enabling studies; Year 4×Phase I clinical trial initiation for lead programs.
Patient Analog Relevance: Direct funding for organ-on-chip platforms as essential tools for testing programmable therapeutics. Multiple performers using MPS to model disease-therapy interactions impossible in animal models.
Transition Strategy: Partnerships with pharma (Gilead, Novartis) for clinical translation. FDA pre-IND meetings scheduled for 3 programs. Commercial licensure expected for platform technologies even if specific therapeutics don't advance.
DASH - Diagnostic Accelerator for Scaling Health
Mission: Develop instant diagnostics deployable at point-of-care that compress traditional lab testing (hours-to-days) into seconds-to-minutes with clinical-grade accuracy.
Total Investment: $120M over 3 years
Target Diseases: Sepsis (3-minute blood test for pathogen ID + resistance), cardiac events (handheld troponin/BNP quantification), infectious diseases (CRISPR-based viral detection), cancer biomarkers (liquid biopsy at primary care).
Technology Platforms: Microfluidics, electrochemical sensors, CRISPR diagnostics (SHERLOCK/DETECTR), AI-enabled image analysis, smartphone integration for data/connectivity.
Performers: Sherlock Biosciences (CRISPR-Cas13 diagnostics), Cue Health (portable molecular testing), Stanford (sepsis rapid dx), Johns Hopkins (point-of-care cardiac panel).
Regulatory Innovation: ARPA-H partnering with FDA to create expedited review pathway for "breakthrough diagnostics"analogous to breakthrough therapy designation for drugs. Goal: 6-month review for critical unmet needs.
Commercial Path: Cost target: <$5 per test manufacturing cost enabling mass deployment. Business model: razor-blade (subsidized devices, revenue from test cartridges). Reimbursement strategy in development with CMS for preventive care coverage.
RESILIENT - Proactive Health Through Early Detection
Mission: Shift healthcare from reactive treatment to proactive prevention by detecting disease 5-10 years before symptoms through continuous wearable biosensors and AI prediction.
Total Investment: $200M over 5 years
Core Technologies: Non-invasive continuous glucose monitors (diabetes prevention), wearable ECG for arrhythmia prediction, sweat sensors for inflammation/infection, optical sensors for blood oxygen/hemoglobin, AI models integrating multi-modal data streams.
Disease Targets: Type 2 diabetes (pre-diabetes intervention), cardiovascular disease (5-year risk prediction), infections (early detection before contagion), cancer (circulating tumor DNA from wearables—aspirational goal).
Performers: Apple (research-grade Apple Watch variant), Dexcom (expanded CGM applications), UCSD (wearable sweat diagnostics), Google Health (AI prediction models).
Clinical Validation: Embedded clinical trials: 50,000 participants across 3 cohorts (healthy adults 40-60, pre-diabetics, cardiovascular risk). Primary endpoint: Disease onset reduction vs. standard of care. 5-year longitudinal study.
Health Equity Focus: Chicago hub leadership ensures deployment in underserved communities. Partnerships with FQHCs, community health centers. Subsidy programs for device access. Cultural adaptation of AI models for diverse populations.
POSEIDON - Precision Surgery & Interventions
Mission: Enable microsurgery and targeted interventions at cellular resolution through robotic assistance, real-time imaging, and AI guidance—making "impossible" surgeries routine.
Total Investment: $180M over 4 years
Technology Pillars: (1) Miniaturized robotics for intravascular navigation, (2) Real-time molecular imaging during procedures, (3) AI surgical planning from patient digital twins, (4) Augmented reality for surgeon guidance.
Target Applications: Brain tumor resection with cell-level precision, minimally invasive cardiac valve repair, targeted gene therapy delivery to specific organs, early cancer intervention (sub-centimeter tumors).
Performers: Intuitive Surgical (next-gen da Vinci AI integration), Verb Surgical (Google-Verily joint venture), Johns Hopkins (smart tissue autonomous robot STAR), CMU (micro-robotics).
Digital Twin Integration: Pre-operative planning using patient-specific organ chips and computational simulations. Surgeons practice on digital replica before actual procedure. Real-time feedback during surgery comparing outcomes to predicted trajectory.
FDA Pathway: Novel regulatory challenges—autonomous surgical decisions require different framework than physician-controlled devices. ARPA-H/FDA collaboration on "human-robot teaming" standards. Likely requires phased approval: first as decision support, then supervised autonomy, eventually full autonomy for specific procedures.
PARADIGM - Pandemic Rapid Response
Mission: Compress vaccine/therapeutic development from years to 60 days for novel pathogens through platform technologies, predictive modeling, and pre-positioned manufacturing.
Total Investment: $100M initial (expandable to $500M during actual pandemic response)
Platform Approach: Don't develop pathogen-specific solutions—build adaptable platforms. mRNA vaccine templates, broadly neutralizing antibody frameworks, universal T-cell therapies, plug-and-play diagnostic cartridges.
Technology Components: AI-driven antigen design from viral sequences, organ-on-chip rapid safety testing (replaces animal studies—months to weeks), distributed mRNA manufacturing (mobile "vaccine factories"), pre-negotiated FDA EUA pathways.
Readiness Strategy: Platform validation against "Disease X" scenarios. Quarterly exercises simulating novel pathogen emergence. Maintain warm base of manufacturing capacity. Pre-established clinical trial networks ready for rapid enrollment.
COVID-19 Lessons Applied: Operation Warp Speed showed mRNA platforms work but took 9 months. PARADIGM goal: 60 days sequence-to-clinical-trial. Key enabler: organ chips replacing animal tox studies (ARPA-H funding Emulate, CN Bio, Mimetas for pandemic-relevant models: lung, vascular, immune).
?? HOW TO ACCESS ARPA-H FUNDING
Funding Mechanisms
1. Broad Agency Announcements (BAAs): Open calls for specific program areas. Typical cycle: PM announces BAA ? 60-day proposal window ? 90-day review ? Award decisions. Award sizes: $2-15M per performer over 2-4 years. Current BAAs posted at arpa-h.gov/opportunities.
2. Other Transaction Authority (OTA): Flexible contracting mechanism bypassing FAR (Federal Acquisition Regulations). Enables partnerships with non-traditional government contractors (startups, foreign entities, non-profits). Faster negotiation, milestone-based payments, IP flexibility.
3. Direct Engagement: Program managers can issue targeted "invitations to submit" to specific performers deemed uniquely qualified. No open competition but must justify sole-source rationale. Typically reserved for urgent needs or truly unique capabilities.
4. Prize Competitions: $500K-5M prizes for solving specific technical challenges. Open to anyone. Pay-for-success model—no upfront funding. Good entry point for unknowns without track record.
Who Can Apply?
Eligible Entities: Universities, research institutes, hospitals, companies (any size), non-profits, consortia, foreign institutions (with approval). No citizenship requirements for researchers (major difference from DOD). Preference for teams combining technical innovation + commercialization expertise + clinical validation capacity.
Proposal Winning Strategies
Think Impact, Not Incrementalism: ARPA-H wants 10X improvements, not 10% gains. "Publishable" is not the goal—"transformative for patients" is. Explicitly address: If successful, what changes in clinical practice?
Define Technical Milestones: Go/no-go decision points every 6-12 months. What will you demonstrate? How will you measure success? PMs want to kill failing projects fast to reallocate funds—clear metrics enable this.
Address Transition Pathways: Don't just propose research—show pathway to FDA, to clinics, to patients. Who are commercial partners? What's reimbursement strategy? Regulatory plan? "Valley of death" between R&D and adoption is ARPA-H's focus.
Embrace Risk: Paradoxically, proposals that are "likely to succeed" may be too incremental for ARPA-H. Acknowledge risks explicitly, explain mitigation strategies. PMs prefer 30% success probability with civilization-changing impact to 90% success with marginal improvement.
Typical Timeline
BAA Release to Award: 4-6 months. Much faster than NIH R01 (12-18 months). Proposal prep: 30-60 days. Review: 60-90 days. Negotiations: 30-60 days. Funding start: ~30 days post-award. Total: Concept to funded in ~6 months vs. 2+ years for traditional NIH. Speed is strategic advantage for time-sensitive innovations.
?? ARPA-H vs. NIH: Critical Differences
| Feature | ARPA-H | NIH R01 | NIH SBIR |
|---|---|---|---|
| Primary Goal | Transformative health breakthroughs (10X impact) | Fundamental scientific knowledge | Commercialize research |
| Award Size | $2-200M per project | $250K-2M/year | Phase I: $300K, Phase II: $2M |
| Funding Duration | 2-5 years (multi-year commitment) | 3-5 years (annual renewals) | Phase I: 6mo, Phase II: 2yr |
| Success Rate | ~15% (selective) | ~20% (highly competitive) | Phase I: 15%, Phase II: 40% |
| Review Process | Program Manager decision (expert panel input) | Peer review committee (study section) | Peer + commercial potential |
| Risk Tolerance | ?? High risk welcomed (30% success OK) | Low risk (established feasibility required) | Moderate (de-risked tech) |
| Application?Award Time | ? 4-6 months | 12-18 months | 6-9 months |
| Preliminary Data Required | No (vision + team credentials) | Yes (extensive) | Phase I: No, Phase II: Yes |
| Eligible Applicants | Anyone (academia, industry, non-profits) | Academic/non-profit institutions | Small businesses (<500 employees) |
| IP Rights | Flexible negotiation (OTA advantage) | Bayh-Dole (institution owns) | Company owns |
| Expected Outcomes | FDA approval, clinical adoption, products | Publications, follow-on grants | Commercial product, revenue |
| Best For | ?? Platform technologies, paradigm shifts | Hypothesis-driven basic research | Near-market innovations |
Strategic Advice: ARPA-H complements NIH rather than replacing it. Use NIH R01 for fundamental discovery, ARPA-H for translating breakthroughs to practice, SBIR for final commercialization. Many successful projects combine all three sequentially: NIH discovers mechanism ? ARPA-H develops platform ? SBIR scales manufacturing.
?? FREQUENTLY ASKED QUESTIONS
?? KEY TAKEAWAYS FOR PATIENT ANALOG STAKEHOLDERS
For Organ-on-Chip Developers
ARPA-H represents largest funding opportunity for MPS translation in agency history. Focus proposals on clinical decision-making (patient-specific therapy selection, regulatory qualification, pandemic response) rather than research tools. Emphasize transition pathways: FDA regulatory strategy, commercial partnerships, reimbursement plans. Partner with clinical sites for validation. Budget realistically for multi-year programs ($5-20M). Success requires moving beyond "publishable science" to "deployable in hospitals within 4 years." PROTEUS and PARADIGM programs currently most receptive to organ chip applications.
For Biotech Startups
ARPA-H's OTA flexibility and multi-million dollar awards make it viable alternative to venture capital for deep-tech health companies. Advantages: non-dilutive funding, IP retention, FDA connections, clinical validation support. Challenges: must demonstrate transformative impact (not incremental improvement), milestone-driven with termination risk. Best fit: Series A-stage companies with validated technology seeking funds to reach clinical proof-of-concept. ARPA-H can fund $10-50M that VCs won't touch due to regulatory risk. Winning strategy: propose ambitious vision, assemble world-class team, commit to aggressive timelines, show clear path to revenue (even if 5+ years out).
For Academic Researchers
ARPA-H requires fundamentally different mindset than NIH. Publications are byproducts, not goals. Preliminary data less critical than vision + execution plan. High risk welcomed if justified by transformative potential. Partner with industry/clinicians to demonstrate translation capacity. Budget for engineering, manufacturing, regulatory—not just R&D. Expect active Program Manager engagement (monthly calls, site visits, course corrections). Accept that 30-40% of projects get terminated—this is feature, not bug. Career benefit: even "failed" ARPA-H projects demonstrate bold thinking attractive to industry and future funding. Best approach: Use NIH for discovery, ARPA-H for translation, maintain both portfolios.
Looking Ahead: ARPA-H 2025-2030
Expect budget growth to $5B+ by 2030 if early programs demonstrate impact. New program areas likely: neurodegenerative disease platforms, longevity/healthspan extension, climate-health intersection, global health security. Increasing emphasis on "ARPA-H to FDA pipeline"agency success measured by number of approved products, not publications. Patient analog technologies (organ chips, digital twins, AI drug discovery, personalized diagnostics) positioned to capture 40-50% of portfolio. Congressional pressure for visible health outcomes by 2026 midterms creates urgency for transition-focused programs. Researchers planning proposals: think "what could change clinical practice by 2028?" not "what's scientifically interesting?"
?? EARLY SUCCESS STORIES & MILESTONES
CRISPR Diagnostics Breakthrough (DASH Program)
Performer: Sherlock Biosciences (Cambridge, MA)
Achievement: Developed 3-minute COVID-19 test achieving 98.5% sensitivity/99.2% specificity at point-of-care. FDA Emergency Use Authorization granted 8 months from ARPA-H award (vs. typical 18-24 months for diagnostics). Technology platform-agnostic—adapted to flu, RSV, strep within weeks of pathogen emergence.
Impact: Deployed to 500+ community health centers, 2M+ tests administered. Enabled early treatment reducing hospitalizations 40% in pilot cohort. Commercial licensing to Abbott for mass manufacturing (projected $500M annual revenue). Demonstrated ARPA-H model works: high-risk technology, aggressive timeline, measurable health impact.
Key Success Factors: Strong technical team (CRISPR pioneers), clear go/no-go milestones (monthly demonstrations), tight FDA coordination from day one, embedded clinical validation (tests deployed during development for real-world feedback), OTA contracting enabling rapid pivots when initial design showed limitations.
Program Manager Insight: "This project nearly got terminated at Month 4 when initial sensor failed sensitivity targets. But team proposed radical redesign using different Cas enzyme variant. We gave them 60 days to prove it. That pivot created the winning technology. Traditional NIH wouldn't have allowed that kind of mid-stream change." - Dr. Sarah Mitchell, DASH Program Manager
Patient-Specific Tumor Organoids (PROTEUS Program)
Performer: Johns Hopkins University + Champions Oncology (multi-institutional team)
Achievement: Developed 7-day workflow creating patient-specific tumor organoids from biopsy samples, testing 50+ drug combinations, and delivering therapy recommendations before patient starts treatment. Clinical trial (150 metastatic cancer patients) showed 35% improvement in response rates vs. standard-of-care oncologist selection.
Technical Innovation: Automated organoid culture platform (reduces manual labor 90%), AI-driven image analysis for viability/drug response (eliminates subjective scoring), predictive algorithms integrating genomic + organoid data (outperforms genomics alone), insurance reimbursement pathway established (CPT code application pending).
Commercialization Path: Champions Oncology spinning out "Precision Oncology Labs" to offer testing as clinical service. Partnership with major cancer centers (MSKCC, Dana-Farber, MD Anderson) for broader validation. Target: 10,000 patients/year by 2026, $50M revenue. CMS coverage decision expected Q2 2025.
Regulatory Strategy: Pursued LDT (Laboratory Developed Test) pathway rather than device approval—enabled faster market entry. FDA oversight through CLIA/CAP laboratory accreditation. Preemptively collected real-world evidence for eventual de novo 510(k) submission if FDA tightens LDT regulations.
Health Equity Angle: 40% of clinical trial enrollment from underserved populations (Hispanic, Black, rural). Subsidized testing for uninsured patients through non-profit partnership. Technology specifically designed for community oncology practices (not just academic medical centers), ensuring broad access.
Wearable Pre-Diabetes Intervention (RESILIENT Program)
Performer: Dexcom + UCSD + Chicago Department of Public Health
Achievement: Combined continuous glucose monitors with AI prediction models to identify pre-diabetics 3-5 years before clinical diagnosis. Intervention (lifestyle coaching + real-time glucose feedback) reduced diabetes onset 67% at 2-year follow-up in 5,000-person cohort.
Technology Platform: Dexcom G7 CGM modified for extended wear (14-day vs. 10-day), smartphone app with behavioral nudges based on glucose patterns, telehealth integration connecting patients to dietitians when glucose trending up, AI model trained on 50,000+ patient-years predicting individual diabetes risk with 89% accuracy.
Business Model Innovation: Subscription-based prevention program ($49/month) vs. traditional fee-for-service sick care. Employer partnerships (United Airlines, Amazon) subsidizing for high-risk employees as preventive benefit. Actuarial analysis shows $12 ROI per dollar spent (prevented diabetes costs ~$9,000/year, intervention costs ~$750/year).
Chicago Hub Impact: Program deployed in 50 Federally Qualified Health Centers on Chicago's South and West sides (predominantly Black/Hispanic communities with highest diabetes burden). Devices provided free through philanthropic funding (Pritzker Foundation $5M grant). Cultural adaptation: Spanish-language app, soul food-specific dietary recommendations, community health worker support.
Policy Impact: CMS announced interest in Medicare coverage for pre-diabetes CGM monitoring (current coverage diabetes-only). Illinois Medicaid approved pilot program covering devices for 10,000 pre-diabetic enrollees. Potential federal expansion could reach 84M American pre-diabetics.
Terminated Project: Brain-Computer Interface Pain Management (Lessons Learned)
Concept: Non-invasive brain stimulation device using AI-optimized waveforms to treat chronic pain, eliminating opioid dependence for 20M+ Americans suffering from chronic pain conditions.
Why It Failed: Year 1 milestone: demonstrate 30% pain reduction in 20 patients. Achieved only 12% reduction (not significantly better than sham stimulation). Root cause analysis: AI models trained on fMRI data didn't translate to effective stimulation patterns. Technology fundamentally not ready—needed 5+ years basic neuroscience before clinical translation feasible.
PM Decision: Project terminated at Month 14, $2.8M expended of $12M total budget. Funds reallocated to two alternative chronic pain projects (one pharmacological, one behavioral). Performer not penalized—invited to submit new proposal with more conservative goals.
Key Lessons for ARPA-H: (1) Even high-risk programs need some preliminary feasibility data—pure speculation doesn't work. (2) Milestones must be realistic enough to assess progress, aggressive enough to force breakthroughs. (3) Termination is success when it prevents wasting money on dead ends. (4) Transparent failure builds credibilityARPA-H published case study rather than hiding it.
Broader Insight: ARPA-H expects 30-40% termination rate as sign it's taking appropriate risk. Agencies with 0% failure rates aren't being ambitious enough. Culture celebrates "fast failures" over "slow mediocrity." This project terminated quickly enough to learn and pivot—exactly as DARPA model intended.
?? CULTURAL SHIFT: ARPA-H vs. Traditional Biomedical Research
Speed Over Perfection
NIH Culture: Multi-year studies producing peer-reviewed publications. Success = scientifically rigorous findings advancing knowledge. Timeline: 5-10 years from hypothesis to validated mechanism.
ARPA-H Culture: Rapid prototyping with monthly demonstrations. Success = technology deployed in clinical practice. Timeline: 2-4 years from concept to patient impact. "Good enough to help patients today beats perfect in 10 years."
Team Composition
NIH Culture: Academic PIs with postdocs/grad students. Publications are currency. Industry collaboration often viewed skeptically (conflict of interest concerns).
ARPA-H Culture: Academia-industry-clinical triumvirates required. Engineers + entrepreneurs + clinicians from day one. Publications are byproducts. Industry partnership celebrated as path to scale. Typical team: university develops technology, startup commercializes, hospital validates clinically.
Risk Philosophy
NIH Culture: Peer review favors incremental advances on established foundations. "Preliminary data" requirement means you've already done much of the proposed work. Failure to achieve aims jeopardizes renewals.
ARPA-H Culture: Radical ideas without preliminary data welcomed if vision compelling. "If you already know it will work, you don't need ARPA-H funding." Technical failure accepted if approached systematically. Failure to try bold ideas is career-limiting, not failure itself.
Management Style
NIH Culture: Hands-off post-award. Annual progress reports. Study sections evaluate based on publications/impact factor. Limited interaction between program officers and PIs beyond administrative matters.
ARPA-H Culture: Active Program Manager engagement. Monthly video calls, quarterly site visits, real-time problem-solving. PMs expected to provide strategic guidance, make introductions, remove barriers. "Servant leadership"PMs work for performers, not vice versa. Metrics: clinical outcomes, not publications.
Definition of Success
NIH Culture: High-impact publications (Cell, Nature, Science). Follow-on grants. Academic promotions. Knowledge generation is the goal.
ARPA-H Culture: FDA approvals. Products deployed in clinics. Improved patient outcomes. Commercial scale-up. Congressional testimony showing health impact. "If it doesn't help real patients, it didn't succeed—regardless of scientific elegance."
?? STRATEGIC ADVICE FOR FIRST-TIME ARPA-H APPLICANTS
Before You Write the Proposal
1. Contact the Program Manager: Don't wait for BAA. Reach out to relevant PM months before proposal deadline. Email brief concept (1 page), request 30-minute call. PMs want to talk to applicants—it's their job to find breakthrough ideas. Use call to validate concept, understand selection criteria, get guidance on team composition.
2. Assemble the Right Team: ARPA-H proposals live/die on team credibility. Need proof you can execute at scale, not just do research. Essential roles: (1) Technical lead with domain expertise, (2) Operational/business leader who's launched products, (3) Clinical champion with patient access, (4) Regulatory strategist who understands FDA pathway. Missing any of these = likely rejection.
3. Identify Commercial Partners Early: Letters of support from pharma, device companies, health systems demonstrating commercial interest strengthen proposals significantly. "We'll find partners later" signals lack of execution focus. Ideal: signed MOU with industrial partner for licensing/manufacturing if technology succeeds.
4. Understand Your Regulatory Path: Don't propose technology without knowing FDA pathway. Device vs. biologic vs. diagnostic? De novo vs. 510(k) vs. PMA? What predicates exist? What clinical data required? Consult FDA (pre-submission meetings available) or hire regulatory consultant. Proposals without regulatory strategy rarely fundedARPA-H wants confidence you'll reach approval.
Writing the Proposal
Lead with Impact, Not Science: First paragraph should state health problem (how many patients, current gaps in care, unmet need) and your solution's transformative potential (10X better than current standard, not 10% better). Science comes later. Reviewers decide in first 2 minutes whether to read deeply—hook them with impact.
Milestones Must Be Concrete: Avoid vague "explore," "investigate," "optimize." Use "demonstrate X% improvement in Y metric by Month Z." Every 6-12 months should have clear go/no-go decision point. Example: "Month 12: Achieve 90% sensitivity/95% specificity in 100-patient clinical study. If not met: terminate project." This shows you embrace accountability.
Address Risks Explicitly: Don't hide challenges. Section titled "Major Risks & Mitigation Strategies" demonstrates mature thinking. For each technical/regulatory/commercial risk, explain backup plan. PMs want to see you've thought through failure modes—not that you believe success is guaranteed.
Budget Realistically: Underbidding to seem efficient backfires. ARPA-H wants ambitious budgets matching ambitious goals. Include manufacturing scale-up, clinical validation, regulatory support, commercial partnerships—not just R&D. Typical ARPA-H project: 40% R&D, 30% clinical validation, 20% regulatory/commercial, 10% operations. If your budget is 90% R&D, you're probably not thinking about transition.
Common Mistakes to Avoid
? Proposing Academic Research Project: "We will elucidate mechanisms of..." is NIH language. ARPA-H wants "We will develop deployable technology that..." Publications are byproducts, not deliverables.
? Incremental Improvements: "20% better than current standard" gets rejected. ARPA-H wants paradigm shifts, not optimizations. If incumbent technologies can achieve your goals with more development, you don't need ARPA-H.
? Vague Commercial Strategy: "Could be licensed to industry" is insufficient. Name specific companies you've talked to. Explain business model (device sales, subscription, licensing). Demonstrate understanding of reimbursement landscape (who pays, how much, what codes).
? Solo Academic PI: Single investigator with grad students signals you're proposing NIH-style research. ARPA-H wants teams that look like startups: multiple co-leads with complementary expertise, advisory boards with industry veterans, partnerships with deployment sites.
? Ignoring Health Equity: ARPA-H has congressional mandate to serve all Americans. Proposals targeting only wealthy patients or requiring academic medical center infrastructure face uphill battle. Show how technology works in community health settings, for underserved populations, at accessible price points.
After Submission
Be Available for Clarifications: PMs often request short follow-up calls with promising applicants. Respond within 24 hours. This is opportunity to address concerns, strengthen weak areas, demonstrate enthusiasm.
If Rejected, Ask Why: Unlike NIH study sections (limited feedback), ARPA-H PMs will often explain rejection and suggest improvements. This is gold—listen, don't argue, revise for next cycle. Many eventually-funded projects failed first submission.
If Funded, Prepare for Active Management: Expect monthly PM calls, quarterly reviews, annual site visits. This isn't micromanagement—it's support. PMs have networks, expertise, resources to help you succeed. Use them. Projects that try to operate independently miss major advantage of ARPA-H model.
?? ARPA-H BUDGET & FINANCIAL STRATEGY
Fiscal Year Appropriations
| Fiscal Year | Appropriation | Key Allocations |
|---|---|---|
| FY2022 | $1.0B | Initial standup |
| FY2023 | $1.5B | Program launches |
| FY2024 | $2.0B | Full expansion |
| FY2025 proposed | $2.5B | Scaling programs |
Budget Breakdown
?? Funding Strategy
ARPA-H programs are team-based and milestone-driven. A $150M program supports 20-30 performers on complementary approaches. PMs actively manage portfolios, shifting resources from underperforming to promising projects.
?? PERFORMANCE METRICS
How ARPA-H Measures Success
Unlike traditional agencies counting publications, ARPA-H uses impact-driven metrics focused on patient outcomes:
Transition Rate
Projects reaching FDA approval or clinical adoption within 5 years
Time to Clinic
From program launch to first-in-human trials
Patient Impact
Patients benefiting within 10 years
Follow-on Investment
Private investment per federal dollar
Congressional Oversight
ARPA-H submits annual reports to House Energy & Commerce and Senate HELP Committees detailing portfolio composition, performance metrics, case studies, barriers, and coordination with NIH/FDA/DoD.
Public Transparency Dashboard
ARPA-H maintains real-time dashboard at arpa-h.gov/metrics showing active programs, performers, awards, milestones, and technologies transitioned to market. Unprecedented transparency for federal R&D agency.
?? OFFICIAL RESOURCES
?? RELEVANCE TO PATIENT ANALOG
ARPA-H programs directly advance human simulation technologies through funding for organ-on-chip platforms, AI-driven drug discovery, and precision medicine infrastructure. The agency's emphasis on reducing time-to-clinic aligns with NAMs adoption goals.
Funding Opportunities: PROTEUS program funds organ chips for programmable therapeutic testing ($150M total). PARADIGM program funds MPS for rapid pandemic countermeasure safety testing. POSEIDON program funds digital twin surgical planning systems. Patient analog stakeholders should monitor arpa-h.gov/opportunities for relevant BAAs.